Cargando…

Oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in Västerbotten, Sweden

OBJECTIVE: To assess the effect of adding an oral glucose tolerance test (OGTT) to fasting plasma glucose (FPG) in terms of detection of type 2 diabetes (T2D) and impaired glucose tolerance (IGT). DESIGN: Retrospective analysis of serial cross-sectional screening study. SETTING: Population-based hea...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosén, Anna, Otten, Julia, Stomby, Andreas, Vallin, Simon, Wennberg, Patrik, Brunström, Mattias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185658/
https://www.ncbi.nlm.nih.gov/pubmed/35676014
http://dx.doi.org/10.1136/bmjopen-2022-062172
_version_ 1784724767833587712
author Rosén, Anna
Otten, Julia
Stomby, Andreas
Vallin, Simon
Wennberg, Patrik
Brunström, Mattias
author_facet Rosén, Anna
Otten, Julia
Stomby, Andreas
Vallin, Simon
Wennberg, Patrik
Brunström, Mattias
author_sort Rosén, Anna
collection PubMed
description OBJECTIVE: To assess the effect of adding an oral glucose tolerance test (OGTT) to fasting plasma glucose (FPG) in terms of detection of type 2 diabetes (T2D) and impaired glucose tolerance (IGT). DESIGN: Retrospective analysis of serial cross-sectional screening study. SETTING: Population-based health examinations within primary care in Västerbotten County, Sweden. PARTICIPANTS: Individuals aged 40- 50 and 60 years with participation from 1985 to 2017. Those with previously diagnosed diabetes and FPG≥7 mmol/L were excluded. PRIMARY AND SECONDARY OUTCOME MEASURES: Prevalence of hyperglycaemia on the OGTT (IGT and T2D defined as 2-hour postload capillary plasma glucose of 8.9–12.1 mmol/L and ≥12.2 mmol/L, respectively). Analyses were further stratified by age, sex and risk factor burden to identify groups at high or low risk of IGT and T2D on testing. The numbers needed to screen (NNS) to prevent one case of T2D through detection and treatment of IGT was estimated, combining prevalence numbers with average progression rates and intervention effects from previous meta-analyses. RESULTS: The prevalence of IGT ranged from 0.9% (95% CI 0.7% to 1.1%) to 29.6% (95% CI 27.4% to 31.7%), and the prevalence of T2D ranged from 0.06% (95% CI 0.02% to 0.11%) to 7.0% (95% CI 5.9% to 8.3%), depending strongly on age, sex and risk factor burden. The estimated NNS to prevent one case of T2D through detection and lifestyle treatment of IGT ranged from 1332 among 40-year-old men without risk factors, to 39 among 60-year-old women with all risk factors combined. CONCLUSIONS: The prevalence of hyperglycaemia on OGTT is highly dependent on age, sex and risk factor burden; OGTT should be applied selectively to high-risk groups to avoid unnecessary testing in the general population.
format Online
Article
Text
id pubmed-9185658
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-91856582022-06-16 Oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in Västerbotten, Sweden Rosén, Anna Otten, Julia Stomby, Andreas Vallin, Simon Wennberg, Patrik Brunström, Mattias BMJ Open Diabetes and Endocrinology OBJECTIVE: To assess the effect of adding an oral glucose tolerance test (OGTT) to fasting plasma glucose (FPG) in terms of detection of type 2 diabetes (T2D) and impaired glucose tolerance (IGT). DESIGN: Retrospective analysis of serial cross-sectional screening study. SETTING: Population-based health examinations within primary care in Västerbotten County, Sweden. PARTICIPANTS: Individuals aged 40- 50 and 60 years with participation from 1985 to 2017. Those with previously diagnosed diabetes and FPG≥7 mmol/L were excluded. PRIMARY AND SECONDARY OUTCOME MEASURES: Prevalence of hyperglycaemia on the OGTT (IGT and T2D defined as 2-hour postload capillary plasma glucose of 8.9–12.1 mmol/L and ≥12.2 mmol/L, respectively). Analyses were further stratified by age, sex and risk factor burden to identify groups at high or low risk of IGT and T2D on testing. The numbers needed to screen (NNS) to prevent one case of T2D through detection and treatment of IGT was estimated, combining prevalence numbers with average progression rates and intervention effects from previous meta-analyses. RESULTS: The prevalence of IGT ranged from 0.9% (95% CI 0.7% to 1.1%) to 29.6% (95% CI 27.4% to 31.7%), and the prevalence of T2D ranged from 0.06% (95% CI 0.02% to 0.11%) to 7.0% (95% CI 5.9% to 8.3%), depending strongly on age, sex and risk factor burden. The estimated NNS to prevent one case of T2D through detection and lifestyle treatment of IGT ranged from 1332 among 40-year-old men without risk factors, to 39 among 60-year-old women with all risk factors combined. CONCLUSIONS: The prevalence of hyperglycaemia on OGTT is highly dependent on age, sex and risk factor burden; OGTT should be applied selectively to high-risk groups to avoid unnecessary testing in the general population. BMJ Publishing Group 2022-06-08 /pmc/articles/PMC9185658/ /pubmed/35676014 http://dx.doi.org/10.1136/bmjopen-2022-062172 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Diabetes and Endocrinology
Rosén, Anna
Otten, Julia
Stomby, Andreas
Vallin, Simon
Wennberg, Patrik
Brunström, Mattias
Oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in Västerbotten, Sweden
title Oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in Västerbotten, Sweden
title_full Oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in Västerbotten, Sweden
title_fullStr Oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in Västerbotten, Sweden
title_full_unstemmed Oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in Västerbotten, Sweden
title_short Oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in Västerbotten, Sweden
title_sort oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in västerbotten, sweden
topic Diabetes and Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185658/
https://www.ncbi.nlm.nih.gov/pubmed/35676014
http://dx.doi.org/10.1136/bmjopen-2022-062172
work_keys_str_mv AT rosenanna oralglucosetolerancetestingasacomplementtofastingplasmaglucoseinscreeningfortype2diabetespopulationbasedcrosssectionalanalysesof146000healthexaminationsinvasterbottensweden
AT ottenjulia oralglucosetolerancetestingasacomplementtofastingplasmaglucoseinscreeningfortype2diabetespopulationbasedcrosssectionalanalysesof146000healthexaminationsinvasterbottensweden
AT stombyandreas oralglucosetolerancetestingasacomplementtofastingplasmaglucoseinscreeningfortype2diabetespopulationbasedcrosssectionalanalysesof146000healthexaminationsinvasterbottensweden
AT vallinsimon oralglucosetolerancetestingasacomplementtofastingplasmaglucoseinscreeningfortype2diabetespopulationbasedcrosssectionalanalysesof146000healthexaminationsinvasterbottensweden
AT wennbergpatrik oralglucosetolerancetestingasacomplementtofastingplasmaglucoseinscreeningfortype2diabetespopulationbasedcrosssectionalanalysesof146000healthexaminationsinvasterbottensweden
AT brunstrommattias oralglucosetolerancetestingasacomplementtofastingplasmaglucoseinscreeningfortype2diabetespopulationbasedcrosssectionalanalysesof146000healthexaminationsinvasterbottensweden